Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments

Autor: John Bartlett, Christine Katlama, Schlomo Staszewski, Hugh McDade, Judy Johnson, Andrew M. Hill, W. Sawyer, Joseph J. Eron

Publikováno v: AIDS. 11:477-483

Objectives: Four randomized double-blind trials have demonstrated that zidovudine/lamivudine (ZDV/3TC) reduces HIV RNA and raises CD4 counts relative to control treatments [ZDV or ZDV/zalcitabine (ddC)]. A meta-analysis of the clinical events in thes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a1a31c1a4fec8a738ec8bdf3c6b02b
https://doi.org/10.1097/00002030-199704000-00011

Evaluation of safety and efficacy of 3tc (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection

Autor: Valerie Kitchen, Hugh McDade, Remko van Leeuwen, Andrew M. Hill, Roland Tubiana, Didier Ingrand, Sven A. Danner, Jonathan Weber, Michael McBride, Charles A. Boucher, Christine Katlama

Publikováno v: Journal of Infectious Diseases, 171(5), 1166-1171. Oxford University Press
Van Leeuwen, R, Katlama, C, Kitchen, V, Boucher, C A B, Tubiana, R, Mc Bride, M, Ingrand, D, Weber, J, Hill, A, Mc Dade, H & Danner, S A 1995, ' Evaluation of safety and efficacy of 3tc (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection : A phase i/ii study ', Journal of Infectious Diseases, vol. 171, no. 5, pp. 1166-1171 . https://doi.org/10.1093/infdis/171.5.1166

In a phase 1/11 study, 7 levelsof3TC therapy (from 0.5 to 20.0 mg/kg/day) were studied in 104 asymptomatic and mildly symptomatic human immunodeficiency virus-infected patients with CD4 cell counts Ȧ4400 × 106/L. Mild and transient episodes of diar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd7b7c463bc5e723ca69cb09b925cb3
https://doi.org/10.1093/infdis/171.5.1166

Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection

Autor: Hugh McDade, Hans Jürgen Stellbrink, Sabine Kinloch, Luc Perrin, David A. Cooper, Anna-Lena Spetz, Jakob Nilsson, Jan Andersson, Thomas E. Fehniger, Homira Behbahani, Brian Gazzard, Anders Sönnerborg, Li-Ean Goh

Publikováno v: The Journal of infectious diseases. 185(9)

Human immunodeficiency virus (HIV)‐s pecific cytotoxic T lymphocyte (CTL) responses are detectable shortly after the acute phase of HIV infection, but they cannot control viral replication and prevent development of chronic immune suppression. This

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781e0a777a4e5f735d222097bbd2a305
https://pubmed.ncbi.nlm.nih.gov/12001057

Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection

Autor: Stephen W. Wietgrefe, Marc K. Jenkins, Carolyn Goodwin, Winston Cavert, Ashley T. Haase, Keith Henry, Zong-ming Chen, Gerald Sedgewick, Kristin Gebhard, Lawrence R. Boies, Roger Mills, Daan W. Notermans, Zhiqiang Zhang, Sven A. Danner, Mary Zupancic, Hugh McDade, Caspar M. Schuwirth

Publikováno v: Zhang, Z Q, Notermans, D W, Sedgewick, G, Cavert, W, Wietgrefe, S, Zupancic, M, Gebhard, K, Henry, K, Boies, L, Chen, Z, Jenkins, M, Mills, R, Mcdade, H, Goodwin, C, Schuwirth, C M, Danner, S A & Haase, A T 1998, ' Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection ', Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 3, pp. 1154-1159 . https://doi.org/10.1073/pnas.95.3.1154
Proceedings of the National Academy of Sciences of the United States of America, 95(3), 1154-1159. National Academy of Sciences

Potent combinations of antiretroviral drugs diminish the turnover of CD4+ T lymphocytes productively infected with HIV-1 and reduce the large pool of virions deposited in lymphoid tissue (LT). To determine to what extent suppression of viral replicat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a31d6a424a4868ec498a379b5df4241
https://europepmc.org/articles/PMC18704/

Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Zidovudine-Experienced Patients

Autor: Clive Loveday, Peter Skinhøj, Lucy Verity, Pierre Dellamonica, P. Richard Harrigan, Schlomo Staszewski, Juan J. Picazo, Hugh McDade, Sven A. Danner, Andrew M. Hill, Margaret A. Johnson

Publikováno v: Staszewski, S, Loveday, C, Picazo, J J, Dellamonica, P, Skinhøj, P, Johnson, M A, Danner, S A, Harrigan, P R, Hill, A M, Verity, L & McDade, H 1996, ' Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients : A randomized controlled comparison with zidovudine monotherapy ', Journal of the American Medical Association, vol. 276, no. 2, pp. 111-117 . https://doi.org/10.1001/jama.276.2.111
Journal of the American Medical Association, 276(2), 111-117. American Medical Association

Objective. - To compare the safety and efficacy of 2 doses of lamivudine given in combination with zidovudine with continued zidovudine monotherapy. Design. - Double-blind, randomized, multicenter, comparative trial of 223 patients treated for 24 wee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b8aa1a5f59e3297f9fbadedc4bdbdc1
https://doi.org/10.1001/jama.1996.03540020033026